Antirrhinum Majus Leaf Beef Liver C12-17 Alkane Ca
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Antirrhinum Majus Leaf Beef Liver C12-17 Alkane Ca
- Complex Botanical-Biological Multi-Ingredient Formulation: Insufficient Data for Drug Repurposing Evaluation
Complex Botanical-Biological Multi-Ingredient Formulation: Insufficient Data for Drug Repurposing Evaluation
One-Sentence Summary
This entry represents a complex mixture of 28 ingredients — including botanical extracts, animal-derived biologics, and synthetic compounds — with no established original indication, no current US or Taiwan market authorization, and no TxGNN predicted indications generated. No drug repurposing analysis is possible at this time due to critical data gaps across all evaluation dimensions. Recommended action is Hold pending fundamental data remediation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established (no regulatory approval found) |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This submission is a heterogeneous mixture of 28 distinct ingredients, including:
- Botanical extracts: Antirrhinum majus leaf, Calendula officinalis, Camellia chekiangoleosa seed oil, Delphinium ajacis seed, Dianthus caryophyllus, Eschscholzia californica, Gardenia jasminoides fruit, Gentiana lutea root, Lonicera canadensis, Viola tricolor, and others
- Animal-derived biologics: Beef liver, Sus scrofa adrenal gland (pig adrenal gland), Corticotropin (ACTH)
- Pharmacologically active compounds: Histamine dihydrochloride
- Industrial chemical: C12-17 alkane (a hydrocarbon mixture)
The TxGNN model is designed to evaluate single active pharmaceutical ingredients (APIs) against the drug–disease knowledge graph. A mixture of this complexity cannot be mapped to a single DrugBank node, which is why no DrugBank ID was assigned and no repurposing candidates were generated.
The presence of corticotropin and histamine dihydrochloride alongside botanical allergen-related extracts suggests this may be a homeopathic desensitization or allergen-immunotherapy preparation, a category that operates under different regulatory and scientific paradigms than conventional pharmaceuticals and is outside the scope of TxGNN-based repurposing analysis.
US Market Information
No US regulatory authorization was found for this formulation. The product is not marketed in the United States under any NDA.
Safety Considerations
No package insert, warning labels, contraindications, or drug interaction data are available for this formulation in accessible regulatory databases.
Please refer to the manufacturer’s product documentation for safety information. Note in particular that corticotropin (ACTH) is a pharmacologically potent hormone with well-documented safety considerations when used in conventional pharmaceutical form; and Nerium oleander (present as a whole plant extract) contains cardiac glycoside toxins. If this product is intended for clinical use, safety characterization of each active component is strongly recommended.
Conclusion and Next Steps
Decision: Hold
Rationale: This formulation cannot be evaluated under the TxGNN drug repurposing framework because it consists of 28 mixed ingredients with no single mappable DrugBank identity, no established indication, no regulatory approval, and no TxGNN predictions. The product profile is more consistent with a homeopathic or complex allergen preparation than a conventional pharmaceutical candidate.
To proceed, the following is needed:
- Clarify product intent: Determine whether this is a homeopathic product, an allergen desensitization agent, or a conventional drug candidate — each pathway has different regulatory and analytical requirements
- Identify the primary active ingredient: If one component (e.g., corticotropin or histamine dihydrochloride) is the intended API, submit that single ingredient as a separate Evidence Pack for TxGNN evaluation
- Obtain DrugBank ID: Required for any knowledge-graph-based repurposing analysis
- Establish original indication: Required for both regulatory positioning and repurposing baseline
- Safety data remediation: Retrieve package insert warnings, contraindications, and pharmacovigilance data for each pharmacologically active component (DG001, DG002 in data gap log)
- Regulatory pathway clarification: Confirm whether this formulation falls under homeopathic drug regulations, dietary supplement regulations, or conventional NDA pathway before pursuing repurposing strategy
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.